NCT03589183 Gut Microbiome in Inflammatory Bowel Disease
| NCT ID | NCT03589183 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kyunghee University Medical Center |
| Condition | Inflammatory Bowel Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2018-04-01 |
| Primary Completion | 2028-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2018-04-01 with a primary completion date of 2028-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Inflammatory bowel disease (IBD) is a chronic inflammatory condition for gastrointestinal tract. There have been numerous studies to reveal dysbiosis of fecal/mucosal microbiome composition in IBD patients but actual trend of dysbiosis is strikingly different among patient's ethnicity. In this background, the investigators have composed a prospective cohort of Korean IBD patients in a large academic referral IBD center. Using an integrated multi-omics bioinformatic analysis, the investigators aim to explore gut microbial signatures along with distinct clinical/genetic features, and their potential interplay in patients with IBD.
Eligibility Criteria
Inclusion Criteria: * Patients with established diagnosis of inflammatory bowel disease, including ulcerative colitis and Crohn disease Exclusion Criteria: * Person with history of using antibiotics or probiotics within previous 2 weeks.
Contact & Investigator
Hyo-Jong Kim, MD PhD
PRINCIPAL INVESTIGATOR
KyungHee University Hospital
Frequently Asked Questions
Who can join the NCT03589183 clinical trial?
This trial is open to participants of all sexes, studying Inflammatory Bowel Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03589183 currently recruiting?
Yes, NCT03589183 is actively recruiting participants. Contact the research team at changkyun.lee@khu.ac.kr for enrollment information.
Where is the NCT03589183 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT03589183 clinical trial?
NCT03589183 is sponsored by Kyunghee University Medical Center. The principal investigator is Hyo-Jong Kim, MD PhD at KyungHee University Hospital. The trial plans to enroll 1,500 participants.